KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $20.2 million.

  • Aurinia Pharmaceuticals' Net Cash Flow rose 44048.19% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year increase of 48948.68%. This contributed to the annual value of $34.6 million for FY2024, which is 17629.2% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Net Cash Flow stood at $20.2 million for Q3 2025, which was up 44048.19% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Net Cash Flow registered a high of $174.3 million during Q4 2021, and its lowest value of -$115.8 million during Q1 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$7.3 million (2023), whereas its average is -$10.5 million.
  • The largest annual percentage gain for Aurinia Pharmaceuticals' Net Cash Flow in the last 5 years was 176807.91% (2024), contrasted with its biggest fall of 32571.98% (2024).
  • Aurinia Pharmaceuticals' Net Cash Flow (Quarter) stood at $174.3 million in 2021, then crashed by 95.34% to $8.1 million in 2022, then plummeted by 69.48% to $2.5 million in 2023, then skyrocketed by 1768.08% to $46.3 million in 2024, then plummeted by 56.39% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q3 2025, -$13.4 million for Q2 2025, and -$17.0 million during Q1 2025.